RecallRadar

FDA Drug recall D-0774-2022

Rifampin for Injection, USP, 600 mg/vial, One Vial per carton, Rx only, Manufactured for: Mylan Institutional LLC, Morgantown, WV 26505 U.S…

On 2022-04-27 the FDA classified a Class II recall of Rifampin for Injection, USP, 600 mg/vial, One Vial per carton, Rx only, Manufactured for: Mylan Institutional LLC, Morgantown, WV 26505 U.S… by Mylan Pharmaceuticals, citing failed Impurities/Degradation Specifications: High out of specification results obtained for related compound during stability testing.

Read the official FDA Drug notice

AgencyFDA Drug
Recall numberD-0774-2022
ClassificationClass II
Statusterminated
Initiated2022-04-07
Published2022-04-27
Last updated2026-09-13 11:52 UTC
CompanyMylan Pharmaceuticals
DistributionUS

Product

Rifampin for Injection, USP, 600 mg/vial, One Vial per carton, Rx only, Manufactured for: Mylan Institutional LLC, Morgantown, WV 26505 U.S.A., NDC 67457-445-60

Reason

Failed Impurities/Degradation Specifications: High out of specification results obtained for related compound during stability testing.

Identifiers

ndc67457-445-60
code_infoLot #: 7008990, exp. date Dec-2022; 7009025, exp. date Feb-2023; 7009085, 7009086, exp. date Apr-2023

Status history

No status changes recorded since RecallRadar first saw this recall on 2026-09-13 11:52 UTC. Current status: terminated.

Source

Official record: https://api.fda.gov/drug/enforcement.json?search=recall_number:%22D-0774-2022%22

RecallRadar indexes public recall notices from the FDA, USDA FSIS, and CPSC. The official agency notice is the authoritative source. Always confirm details at the linked source before acting.